WO1998044096A3 - Mycobacterium recombinant vaccines - Google Patents

Mycobacterium recombinant vaccines Download PDF

Info

Publication number
WO1998044096A3
WO1998044096A3 PCT/US1998/006056 US9806056W WO9844096A3 WO 1998044096 A3 WO1998044096 A3 WO 1998044096A3 US 9806056 W US9806056 W US 9806056W WO 9844096 A3 WO9844096 A3 WO 9844096A3
Authority
WO
WIPO (PCT)
Prior art keywords
mycobacterium
nontoxic
immuno
cloning
recombinant vaccines
Prior art date
Application number
PCT/US1998/006056
Other languages
French (fr)
Other versions
WO1998044096A2 (en
Inventor
Abdel Hakim Labidi
Original Assignee
Cytoclonal Pharmaceutics Inc
Abdel Hakim Labidi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytoclonal Pharmaceutics Inc, Abdel Hakim Labidi filed Critical Cytoclonal Pharmaceutics Inc
Priority to JP54183198A priority Critical patent/JP2001518781A/en
Priority to EP98913194A priority patent/EP0973881A2/en
Priority to BR9808441-0A priority patent/BR9808441A/en
Priority to CA002284736A priority patent/CA2284736A1/en
Priority to AU67804/98A priority patent/AU6780498A/en
Publication of WO1998044096A2 publication Critical patent/WO1998044096A2/en
Publication of WO1998044096A3 publication Critical patent/WO1998044096A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Mycobacterium recombinant vaccines for treatment of intracellular diseases have been developed utilizing an antigen delivery system in the form of Mycobacterium strains, a genetic transfer system in the form of cloning nonpathogenic and expression vectors, and related technologies to provide products combining nontoxic immuno-regulating Mycobacterium adjuvants, nontoxic immuno-stimulating exogenous antigens specific for a variety of diseases, and nontoxic amounts of cytokines that boost the TH-1 pathway. Cloning and expression Mycobacterium vectors include both extra-nuclear and integrative vectors.
PCT/US1998/006056 1997-03-28 1998-03-27 Mycobacterium recombinant vaccines WO1998044096A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP54183198A JP2001518781A (en) 1997-03-28 1998-03-27 Mycobacterium recombinant vaccine
EP98913194A EP0973881A2 (en) 1997-03-28 1998-03-27 Mycobacterium recombinant vaccines
BR9808441-0A BR9808441A (en) 1997-03-28 1998-03-27 Pharmaceutical composition for administration to an animal, carrier vector, vectors for carrying and expressing selected genes in escherichia coli and a strain of mycobacterium, process for administering to an animal an effective amount of the pharmaceutical composition, and culture medium.
CA002284736A CA2284736A1 (en) 1997-03-28 1998-03-27 Mycobacterium recombinant vaccines
AU67804/98A AU6780498A (en) 1997-03-28 1998-03-27 Mycobacterium recombinant vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4284997P 1997-03-28 1997-03-28
US60/042,849 1997-03-28

Publications (2)

Publication Number Publication Date
WO1998044096A2 WO1998044096A2 (en) 1998-10-08
WO1998044096A3 true WO1998044096A3 (en) 1999-01-14

Family

ID=21924071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/006056 WO1998044096A2 (en) 1997-03-28 1998-03-27 Mycobacterium recombinant vaccines

Country Status (6)

Country Link
EP (1) EP0973881A2 (en)
JP (1) JP2001518781A (en)
AU (1) AU6780498A (en)
BR (1) BR9808441A (en)
CA (1) CA2284736A1 (en)
WO (1) WO1998044096A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1272213T3 (en) * 2000-04-06 2006-07-10 Seer Pharmaceuticals Llc Microbial delivery system
EP1369127B1 (en) 2001-02-20 2010-04-14 MARUHO Co., Ltd. Novel medicinal use of alpha antigen or alpha antigen gene
WO2003006035A1 (en) * 2001-07-10 2003-01-23 Stanford Rook Limited Anti-emetic compositions comprising mycobacterial material
JP5994127B2 (en) * 2011-09-13 2016-09-21 日本ビーシージー製造株式会社 New recombinant BCG vaccine
CN108285881B (en) * 2018-01-04 2021-06-08 广州大学 Mycobacterium with synchronous electricity generation and denitrification activity and application thereof
EP4233912A3 (en) * 2018-02-19 2023-11-01 Universidad De Zaragoza Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001783A1 (en) * 1990-07-16 1992-02-06 Albert Einstein College Of Medicine Of Yeshiva University Dna capable of site-specific integration into mycobacteria
WO1995003417A2 (en) * 1993-07-22 1995-02-02 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
US5583038A (en) * 1991-10-21 1996-12-10 Medimmune, Inc. Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
US5599545A (en) * 1990-05-07 1997-02-04 University College London Mycobacterium as adjuvant for antigens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599545A (en) * 1990-05-07 1997-02-04 University College London Mycobacterium as adjuvant for antigens
WO1992001783A1 (en) * 1990-07-16 1992-02-06 Albert Einstein College Of Medicine Of Yeshiva University Dna capable of site-specific integration into mycobacteria
US5583038A (en) * 1991-10-21 1996-12-10 Medimmune, Inc. Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
WO1995003417A2 (en) * 1993-07-22 1995-02-02 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERGERS J J ET AL: "LIPOSOMES AS DELIVERY SYSTEMS IN THE PREVENTION AND TREATMENT OF INFECTIONS DISEASES", PHARMACY WORLD AND SCIENCE, vol. 17, no. 1, 27 January 1995 (1995-01-27), pages 1 - 11, XP000501375 *
DAVID M. ET AL.: "A stable Escherichia coli-Mycobacterium smegmatis plasmid shuttle vector containing the mycobacteriophage D29 origin", PLASMID, vol. 28, no. 3, November 1992 (1992-11-01), pages 267 - 271, XP002072080 *

Also Published As

Publication number Publication date
WO1998044096A2 (en) 1998-10-08
BR9808441A (en) 2000-05-23
CA2284736A1 (en) 1998-10-08
JP2001518781A (en) 2001-10-16
AU6780498A (en) 1998-10-22
EP0973881A2 (en) 2000-01-26

Similar Documents

Publication Publication Date Title
Kaufmann et al. Impact of intracellular location of and antigen display by intracellular bacteria: implications for vaccine development
EP1303299B1 (en) Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens
US6855320B2 (en) Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
EP1658772A3 (en) Receptor specific transepithelial transport of immunogens
CA2293489A1 (en) Inhibitors of dna immunostimulatory sequence activity
AU3041295A (en) Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
WO1998002546A3 (en) Dna immunization against chlamydia infection
AU4078599A (en) Expression vectors for stimulating an immune response and methods of using the same
CA2182303A1 (en) Method of preparing a viral vector by homologous intermolecular recombination
AU2003278729A1 (en) Regulated bacterial lysis for gene vaccine vector delivery and antigen release
MX9707021A (en) Il-17 receptor.
NZ281409A (en) Medicaments for cancer treatment using peptides based on a 9 AA epitiope derived from mage -3 that induces ctls
MY119003A (en) Bacterial antigens and vaccine compositions
AU1955088A (en) Avirulent microbes, incapable of producing functional adenylate cyclase and cyclic AMP
WO2001098335A3 (en) Transgenic algae for delivering antigens to an animal
WO2003076603A3 (en) Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
NZ503039A (en) Recombinant porcine adenovirus vector
AU2145188A (en) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
Handman Leishmania vaccines: old and new
WO2002053181A8 (en) Enterohemorragic escherichia coli vaccine
DE69928556D1 (en) IMMUNOMODULATION BY GENETIC MODIFICATION OF DENDRITIC CELLS AND B-CELLS
WO1998044096A3 (en) Mycobacterium recombinant vaccines
WO2000061724A3 (en) Anti-bacterial vaccine compositions
AU3036297A (en) Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin
EP0331356A3 (en) Expression of hiv binding proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2284736

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

Ref document number: 1998 541831

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/008868

Country of ref document: MX

Ref document number: 09402146

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 67804/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998913194

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998913194

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998913194

Country of ref document: EP